Emmaus Life Sciences Appoints New Auditor

TL;DR

Emmaus Life Sciences swapped auditors, bringing in CohnReznick LLP for the 2024 audit.

AI Summary

Emmaus Life Sciences, Inc. announced on October 22, 2024, that it has appointed a new independent registered public accounting firm, CohnReznick LLP, to audit its financial statements for the fiscal year ending December 31, 2024. This change follows the resignation of its previous auditor, BDO USA, LLP.

Why It Matters

A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors should monitor.

Risk Assessment

Risk Level: medium — A change in auditors, especially without a detailed explanation, can sometimes indicate accounting concerns or disagreements, warranting closer investor scrutiny.

Key Players & Entities

• Emmaus Life Sciences, Inc. (company) — Registrant
• CohnReznick LLP (company) — Newly appointed independent registered public accounting firm
• BDO USA, LLP (company) — Previous independent registered public accounting firm
• October 22, 2024 (date) — Date of the earliest event reported
• December 31, 2024 (date) — Fiscal year end for which the audit will be conducted

FAQ

Filing Documents

• ea0218652-8k_emmaus.htm (8-K) — 26KB
• 0001213900-24-090765.txt ( ) — 190KB
• emma-20241022.xsd (EX-101.SCH) — 3KB
• emma-20241022_lab.xml (EX-101.LAB) — 33KB
• emma-20241022_pre.xml (EX-101.PRE) — 22KB
• ea0218652-8k_emmaus_htm.xml (XML) — 3KB

01 Changes in Registrant's Certifying

Item 4.01 Changes in Registrant's Certifying Accountant On October 22, 2024, the Audit Committee of the Board of Directors of Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") engaged Marcum LLP as our independent registered public accounting firm for the quarter ended September 30, 2024 and the year ending December 31, 2024. During the years ended December 31, 2023 and 2022 and subsequent interim periods through the date of this Current Report, we did not consult Marcum LLP regarding any of the matters described in Item 304(a)(2) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits See the accompanying Index to Exhibits, which is incorporated herein by reference. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 25, 2024 Emmaus Life Sciences, Inc. By: /s/ YASUSHI NAGASAKI Name: Yasushi Nagasaki Title: Chief Financial Officer 2 INDEX TO EXHIBITS Exhibit Number Description 104 Cover Page Interactive Date File (embedded within Inline XBRL document) 3

View Full Filing

View this 8-K filing on SEC EDGAR